You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

Details for Patent: 10,738,037

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,738,037 protect, and when does it expire?

Patent 10,738,037 protects ROZLYTREK and is included in one NDA.

This patent has eighteen patent family members in thirteen countries.

Summary for Patent: 10,738,037

Title:	Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2- -(tetrahydro-pyran-4-ylamino)-benzamide
Abstract:	The present invention relates to a new crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2- -(tetrahydro-pyran-4-ylamino)-benzamide, process for its preparation, its utility in treating diseases caused by deregulated protein kinase activity and pharmaceutical compositions containing it.
Inventor(s):	Candiani; Ilaria (Busto Arsizio, IT), Ottaiano; Giovanni (Corbetta Milan, IT), Tomasi; Attilio (Milan, IT)
Assignee:	NERVIANO MEDICAL SCIENCES S.R.L. (Nerviano (MI), IT)
Application Number:	16/301,826
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound; Process; Dosage form;

Drugs Protected by US Patent 10,738,037

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Genentech Inc	ROZLYTREK	entrectinib	CAPSULE;ORAL	212725-001	Aug 15, 2019		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y		TREATMENT OF COLORECTAL CANCER THAT HAS A NEUROTROPHIC TYROSINE RECEPTOR KINASE(NTRK) GENE FUSION	⤷ Sign Up
Genentech Inc	ROZLYTREK	entrectinib	CAPSULE;ORAL	212725-002	Aug 15, 2019		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		TREATMENT OF COLORECTAL CANCER THAT HAS A NEUROTROPHIC TYROSINE RECEPTOR KINASE(NTRK) GENE FUSION	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 10,738,037

PCT Information
PCT Filed	May 18, 2017	PCT Application Number:	PCT/EP2017/061919
PCT Publication Date:	November 30, 2017	PCT Publication Number:	WO2017/202674

International Family Members for US Patent 10,738,037

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017271458	⤷ Sign Up
Brazil	112018073951	⤷ Sign Up
Canada	3024208	⤷ Sign Up
China	109153669	⤷ Sign Up
European Patent Office	3464276	⤷ Sign Up
European Patent Office	3967689	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.